<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pioglitazone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pioglitazone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pioglitazone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10977" href="/d/html/10977.html" rel="external">see "Pioglitazone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709212"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Congestive heart failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones, including pioglitazone, can cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of pioglitazone, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, manage the heart failure according to the current standards of care. Furthermore, discontinuation or dose reduction of pioglitazone must be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F210230"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Actos</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867946"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL Pioglitazone [DSC];</li>
<li>ACH-Pioglitazone;</li>
<li>ACT Pioglitazone;</li>
<li>APO-Pioglitazone;</li>
<li>JAMP-Pioglitazone;</li>
<li>MINT-Pioglitazone;</li>
<li>PMS-Pioglitazone [DSC];</li>
<li>PRO-Pioglitazone [DSC];</li>
<li>SANDOZ Pioglitazone [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F210256"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Thiazolidinedione</li></ul></div>
<div class="block doa drugH1Div" id="F210234"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> May require a dose reduction of insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia; consider discontinuation or dose reduction of insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-30291106','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-30291106','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin; may be preferred when avoidance of hypoglycemia is desirable. Use has been associated with an increased risk of heart failure, and risk is increased with concomitant insulin use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2023'])">Ref</a></span>). Avoid use in patients with preexisting heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106','lexi-content-ref-Inzucchi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106','lexi-content-ref-Inzucchi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15 to 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Dosage adjustment: May increase in 15 mg/day increments every 4 to 12 weeks if needed to achieve glycemic goals (maximum: 45 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-16214598','lexi-content-ref-Inzucchi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-16214598','lexi-content-ref-Inzucchi.1'])">Ref</a></span>). Discontinue use if signs or symptoms of heart failure develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53e12625-207c-4e66-ada3-490cdff22b05">Insulin resistance/prediabetes, secondary prevention of atherosclerotic cardiovascular disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insulin resistance/prediabetes, secondary prevention of atherosclerotic cardiovascular disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used in patients with insulin resistance/prediabetes who have a history of stroke or transient ischemic attack (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2023','lexi-content-ref-26886418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2023','lexi-content-ref-26886418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15 mg once daily. Increase in 15 mg/day increments every 4 weeks if tolerated to a target dose of 45 mg once daily. Discontinue use if signs or symptoms of heart failure develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26886418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26886418'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ed14d1d-fd2a-4fdd-8f42-6c0afe901781">Metabolic dysfunction associated steatohepatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic dysfunction associated steatohepatitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider use in patients with biopsy-confirmed metabolic dysfunction associated steatohepatitis who also have type 2 diabetes mellitus; treatment may also be considered in patients with prediabetes, though risks may more closely match benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28714183','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-27062661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28714183','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-27062661'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 30 mg once daily for 2 months, then increase dose to 45 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798'])">Ref</a></span>). Consider limiting dose to ≤30 mg/day if worsening heart failure is a concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>); patients with cardiovascular disease were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991025"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12680885','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12680885','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed; no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eckland.2000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eckland.2000'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed due to high protein binding (expert opinion); no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988240"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients without cirrhosis:</i></b> No dosage adjustment necessary; use with caution if baseline liver tests are abnormal; some studies involving patients with metabolic dysfunction associated steatohepatitis (MASH) excluded patients with baseline LFTs (eg, AST, ALT) that were ≥2.5 to 3 times ULN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17135584','lexi-content-ref-27322798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17135584','lexi-content-ref-27322798'])">Ref</a></span>). Once initiated, repeat LFTs periodically (eg, every 2 to 3 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19670918','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19670918','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note: </b>Studies in patients with MASH, with or without type 2 diabetes mellitus, excluded patients with other causes of liver disease (eg, hepatitis C, alcohol-associated fatty liver disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18718471','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-20427778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18718471','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-20427778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients with cirrhosis: </i></b>Use in patients with cirrhosis is <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24669954','lexi-content-ref-35252271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24669954','lexi-content-ref-35252271'])">Ref</a></span>); studies in patients with MASH, with or without type 2 diabetes mellitus, excluded patients with cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18718471','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-20427778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18718471','lexi-content-ref-17135584','lexi-content-ref-29223443','lexi-content-ref-27322798','lexi-content-ref-20427778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment during therapy:</b> Drug-induced liver injury associated with pioglitazone is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21609444','lexi-content-ref-11431595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21609444','lexi-content-ref-11431595'])">Ref</a></span>). If liver injury is suspected (eg, fatigue, jaundice, dark urine), interrupt therapy, measure serum liver tests, and investigate possible etiologies:</p>
<p style="text-indent:-2em;margin-left:4em;">If an alternative etiology is not identified and ALT &gt;3 times ULN: Do not reinitiate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">If an alternative etiology is identified and ALT elevated (but &lt;3 times ULN) <b>or</b> total bilirubin elevated (but &lt;2 times ULN): May reinitiate with caution.</p></div>
<div class="block doe drugH1Div" id="F210235"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56321035"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bladder cancer</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone may increase the risk of <b>bladder carcinoma</b>. A meta-analysis of randomized controlled trials and observational data support this association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>). Older data suggest the risk may be as high as 40% with duration &gt;24 months and cumulative doses &gt;28,000 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22653981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22653981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; not clearly established but thought to be associated with activation of peroxisome proliferator activated receptor gamma (PPAR γ), which may alter tumor growth and progression in non-adipose cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; cases and risk generally occur with long-term use and high-dose exposure; however, there have been cases diagnosed within the first year of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative doses (&gt;28,000 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (&gt;24 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• European ethnicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Caucasian race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29476615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29476615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of bladder cancer</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones (TZDs) may increase the risk of <b>bone fractures</b>, but the risk associated with pioglitazone is conflicting. Analysis of safety data after 5 years of pioglitazone therapy in patients without diabetes from the Insulin Resistance Intervention after Stroke Trial (IRIS) showed an absolute risk increase of 1.6% to 4.9% and relative risk increase of 47% to 60%. Fractures were typically low energy, not related to stress or pathology, and not serious (ie, not requiring surgery or hospitalization) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>). Fractures were in the spine, rib, foot, fibula, radius, tibia, humerus, and hip with no one skeletal region more affected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>). In contrast, a meta-analysis of patients with type 2 diabetes mellitus found the risk of fracture comparable to other hyperglycemic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>). Cited explanations for a correlation from prior evidence include the study populations (ie, mostly older adults and post-menopausal females), as well as older TZDs used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>). Discontinuation of TZDs may attenuate adverse bone effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; TZDs activate peroxisome proliferator activated receptor gamma (PPAR γ) which is expressed in bone as well as various other tissues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>). Activation creates an imbalance of bone remolding, including changes in bone marrow structure and function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100','lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100','lexi-content-ref-27935736'])">Ref</a></span>). Additionally, TZDs have been associated with a decrease in estrogen synthesis, which may exacerbate the effects on bone metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; IRIS data indicates an increased risk after 2 years of pioglitazone therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of drug therapy (&gt;2 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27935736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27935736'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Retinopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29683100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29683100'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure/edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone has been with associated with an increased risk of <b>cardiac failure</b>/worsening of cardiac failure and dose-dependent <b>edema</b> but has not been shown to have adverse effects on cardiac function structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29037211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29037211'])">Ref</a></span>). Symptoms are reversible with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12706937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12706937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Plasma volume increase appears to be the underlying etiology. Reduction in renal excretion of sodium and increase in sodium and free water retention is consistently thought of as the primary contributor to this plasma volume increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>). Other exacerbating mechanisms could be increased sympathetic nervous system activity, alteration in endothelial permeability, and peroxisome proliferator activated receptor gamma (PPAR γ) mediated expression of vascular permeability growth factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27127397','lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27127397','lexi-content-ref-14693998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; within the first few weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14583425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14583425'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of pedal edema or treatment with loop diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease/significant aortic or mitral valve heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29037211','lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29037211','lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of drugs associated with fluid retention or pedal edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use with other glucose lowering therapies (especially insulin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (&gt;70 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Left ventricular hypertrophy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes for &gt;10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney failure (creatinine &gt;2 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14693998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14693998'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older thiazolidinediones (TZDs) have stronger evidence of liver injury and increased liver function tests than pioglitazone. Acute <b>hepatic failure</b> has been reported with pioglitazone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623674','lexi-content-ref-11900497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623674','lexi-content-ref-11900497'])">Ref</a></span>). Resolution of symptoms may occur within 1 to 6 months of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15266041','lexi-content-ref-11900497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15266041','lexi-content-ref-11900497'])">Ref</a></span>). Pioglitazone (in combination with lifestyle modifications) has been shown to improve hepatic fat in patients with diabetes and liver histology, steatosis, and resolution of nonalcoholic fatty liver disease (NAFLD) in patients without diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31783920','lexi-content-ref-23930133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31783920','lexi-content-ref-23930133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; exact mechanism is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25727309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25727309'])">Ref</a></span>). Excess free fatty acids in the insulin resistant state may be directly toxic to hepatocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25941563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25941563'])">Ref</a></span>), which may support the positive finding in NAFLD studies with pioglitazone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25941563','lexi-content-ref-31783920','lexi-content-ref-23930133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25941563','lexi-content-ref-31783920','lexi-content-ref-23930133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; occurs 1 to 7 months after therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15266041','lexi-content-ref-11900497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15266041','lexi-content-ref-11900497'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F210201"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions and incidences reported are associated with monotherapy unless otherwise stated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (3% to 27%; including exacerbation of edema)<span class="lexi-table-link-container"> (<a aria-label="Edema table link" class="lexi-table-link" data-table-id="lexi-content-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Edema" frame="border" id="lexi-content-edema" rules="all">
<caption>
<b>Pioglitazone: Adverse Reaction: Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,605</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,633</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">45 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">169</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">259</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">275</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">259</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">259</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine and metabolic: Hypoglycemia (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure (8%; including worsening of heart failure)<span class="lexi-table-link-container"> (<a aria-label="Cardiac Failure table link" class="lexi-table-link" data-table-id="lexi-content-cardiac-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cardiac-failure')">table 2</a>)</span><span class="table-link" style="display:none;">Cardiac Failure</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cardiac Failure" frame="border" id="lexi-content-cardiac-failure" rules="all">
<caption>
<b>Pioglitazone: Adverse Reaction: Cardiac Failure</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,605</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,633</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (6%), bone fracture (females: 5%; males: 2%)<span class="lexi-table-link-container"> (<a aria-label="Bone Fracture table link" class="lexi-table-link" data-table-id="lexi-content-bone-fracture" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bone-fracture')">table 3</a>)</span><span class="table-link" style="display:none;">Bone Fracture</span>, myalgia (5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bone Fracture" frame="border" id="lexi-content-bone-fracture" rules="all">
<caption>
<b>Pioglitazone: Adverse Reaction: Bone Fracture</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">870</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">905</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (5%), sinusitis (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic<b>: </b>Bladder carcinoma<span class="lexi-table-link-container"> (<a aria-label="Bladder Carcinoma table link" class="lexi-table-link" data-table-id="lexi-content-bladder-carcinoma" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bladder-carcinoma')">table 4</a>)</span><span class="table-link" style="display:none;">Bladder Carcinoma</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bladder Carcinoma" frame="border" id="lexi-content-bladder-carcinoma" rules="all">
<caption>
<b>Pioglitazone: Adverse Reaction: Bladder carcinoma</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pioglitazone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,605</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,633</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum triglycerides, increased HDL cholesterol, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Floyd 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity, macular edema (new-onset or worsening) (Oshitari 2008)</p></div>
<div class="block coi drugH1Div" id="F210213"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pioglitazone or any component of the formulation; NYHA Class III/IV heart failure (initiation of therapy)</p>
<p style="text-indent:0em;margin-top:2em;">Canadian labeling: Additional contraindications (not is U.S. labeling): Any stage of heart failure (eg, NYHA Class I, II, III, IV); serious hepatic impairment; active bladder cancer; history of bladder cancer; uninvestigated macroscopic hematuria; pregnancy</p></div>
<div class="block war drugH1Div" id="F210198"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: May decrease hemoglobin/hematocrit; effects may be related to increased plasma volume.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: The risk of hypoglycemia is increased when pioglitazone is combined with insulin or other diabetic medications; dosage adjustment of concomitant hypoglycemic agents may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy and all diabetic patients should have regular eye exams.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight gain: Dose-related weight gain observed with use; mechanism unknown but likely associated with fluid retention and fat accumulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes, type 1: Mechanism requires the presence of insulin; therefore, use in type 1 diabetes or diabetic ketoacidosis is not recommended.</p></div>
<div class="block foc drugH1Div" id="F210208"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actos: 15 mg, 30 mg, 45 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 45 mg</p></div>
<div class="block geq drugH1Div" id="F210194"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F210214"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Actos Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $15.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $23.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $25.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pioglitazone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $7.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $10.71 - $10.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $11.61 - $11.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867947"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 45 mg</p></div>
<div class="block adm drugH1Div" id="F210210"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered without regard to meals</p></div>
<div class="block meg drugH1Div" id="F9350995"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F021073s049lbl.pdf%23page%3D35&amp;token=wXz3OMCq4EBwQEC%2Bje2%2B723VcOlg7iIO2d58exHXUHjSf9m39n5WE2ygTHsH%2FOYxom8ADUkxQhG6fTxwb0sNnhWOGhB8%2FIUUphV%2BxBSTvwbSTu9%2FxHjnsVFvh1lOl1Kf&amp;TOPIC_ID=10216" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf#page=35</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F210209"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment: </b> As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus</p></div>
<div class="block off-label drugH1Div" id="F55685591"><span class="drugH1">Use: Off-Label: Adult</span><p>Insulin resistance/prediabetes, secondary prevention of atherosclerotic cardiovascular disease; Metabolic dysfunction associated steatohepatitis</p></div>
<div class="block mst drugH1Div" id="F210263"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Actos may be confused with Actidose, Actonel</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tiazac: Brand name for pioglitazone [Chile], but also the brand name for dilTIAZem [U.S, Canada]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F210250"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F210203"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the hypoglycemic effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inducers (Moderate): May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit the pioglitazone dose to 15 mg daily and monitor for increased pioglitazone toxicities (eg, hypoglycemia) when used in combination with strong CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.  Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: May enhance the fluid-retaining effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53394882"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Thiazolidinediones may cause ovulation in anovulatory premenopausal patients, increasing the risk of unintended pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Thiazolidinediones are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F210215"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of pioglitazone in pregnancy is limited (Glueck 2003; Ortega-Gonzalez 2005; Ota 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than pioglitazone are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F210216"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pioglitazone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F210217"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on American Diabetes Association recommendations is an integral part of therapy</p></div>
<div class="block mop drugH1Div" id="F210206"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Closely monitor for signs and symptoms of heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases or in NYHA class I or II (systolic) heart failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Type 2 diabetes mellitus, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Serum glucose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Liver enzymes (ALT, AST, alkaline phosphatase, and total bilirubin) prior to initiation in all patients (with or without liver disease); continue routine periodic monitoring during treatment only in patients with liver disease or suspected liver disease; monitor for signs/symptoms of liver injury closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Signs and symptoms of fluid retention or heart failure; weight gain; signs/symptoms of bladder cancer (dysuria, macroscopic hematuria, dysuria, urinary urgency); ophthalmic exams.</p></div>
<div class="block rer drugH1Div" id="F6258749"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (ADA 2023, AACE [Samson 2023]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Older adults (≥65 years of age) (ADA 2023): </i>
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F210197"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity. Pioglitazone is a potent and selective agonist for peroxisome proliferator-activated receptor-gamma (PPARgamma). Activation of nuclear PPARgamma receptors influences the production of a number of gene products involved in glucose and lipid metabolism. PPARgamma is abundant in the cells within the renal collecting tubules; fluid retention results from stimulation by thiazolidinediones which increases sodium reabsorption.</p></div>
<div class="block phk drugH1Div" id="F210212"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Delayed</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Glucose control: Several weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (apparent): 0.63 ± 0.41 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Pioglitazone &gt;99% and active metabolites &gt;98%; primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (99%) via CYP2C8 and 3A4 to active and inactive metabolites; M-III and M-IV are major circulating active metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: 3 to 7 hours; M-III and M-IV metabolites: 16 to 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 hours; delayed with food</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (15% to 30%) and feces as metabolites</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F210218"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glacera | Glados | Glustin | Ipoz | Pio | Pioglin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actos | Cereluc | Diaben P | Pioglit | Zatium</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon Accord | Pioglitazon G.L. | Pioglitazon Hexal | Pioglitazon Stada | Pioglitazon Teva | Pioglitazone Actavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acpio | Actaze | Actos | Apo pioglitazone | Cm Pioglitazone | Noumed pioglitazone | Pharmacor pioglitazone | Pioglitazone an | Pioglitazone GA | Pioglitazone pfizer | Pioglitazone sandoz | Pizaccord | Prioten | Terry white chemists pioglitazone | Vexazone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Actose | Adpas | Diaglit | Diatus | Glitazon | Glucozon | Lit | Ogli | Pidus | Piglit | Piodar | Pioglin | Piol | Piolit | Piozena | Tos</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Actos</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lispecip | Pizona</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Actos | Aglitil | Clo pioglitazo | Cloridrato de pioglitazona | Glicopio | Pioglit | Piotaz | Stanglit</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon Actavis | Pioglitazon Mepha | Pioglitazon Mepha Teva | Pioglitazon sandoz</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Diaglycan | Pionorm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actos | Diabestat | Tiazac | Zatium</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Actins | Actos | Actus | Ai ke ta | Ai ting | Duo ying | Ka si ping | Kai bao wei yuan | Ke cheng | Lie luo | Rui tong</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Duplot | Glucemin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Actos | Novapio | Pioglitazon Actavis | Pioglitazon apotex | Pioglitazon Mylan | Pioglitazone accord | Pioglitazone Teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon Aurobindo | Pioglitazon micro</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Actos | Zatium</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Actos | Zatium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone accord | Pioglitazone Teva | Zipion</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Actos | Actozone | Diabetin | Diabetonorm | Ensudyne | Glustazon | Glustin | Hi glitazone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glustin | Pioglitazona accord | Pioglitazona Actavis | Pioglitazona Aurobindo | Pioglitazona aurovitas | Pioglitazona Cinfa | Pioglitazona edigen | Pioglitazona Kern | Pioglitazona normon | Pioglitazona Sandoz | Pioglitazona Stada | Pioglitazona Tecnigen | Pioglitazona Teva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon orion | Pioglitazone accord | Pioglitazone Actavis | Pioglitazone sandoz | Pioglitazone Teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Actos</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glidipion | Pioglitazone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glitact | Glizon | Pioglitazone mylan | Pioglitazone sandoz | Raglitan | Sahar | Zipion</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Actos | Apo pioglitazone | Glitter | Pioglitazone | Pioglitazone Actavis | Pms pioglitazone | Zolid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon Pliva | Pioglitazone Teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Gliabetes | Opiglit | Pioglitazone | Pioglitazone HCL | Pionix | Prabetic | Tazovell</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone | Pioglitazone accord</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adglim p | Alpiozon | Betapride | Biodib | Cureglit | Diaglit | Diavista | Dibizone | Drpg | G-tase | Geoglit | Glita | Glitaris | Glitase | Glitastar | Glito | Glitter | Glizone | Glufit | Glycopy | Gp | K-pio | Lupiglit | Oglo | Opam | P-glitz | Path | Pazo | Pepar | Pio-g | Piobir | Piocon | Piodart | Piofix | Pioglar | Pioglaz | Pioglit | Pioglitex | Pioglu | Piohope | Piokap | Piokind | Piolee | Piolem | Piolet | Pioli | Piomed | Piomerc | Piomeri | Pioneer | Pionorm | Piopar | Piopill | Piopod | Piorest | Piosafe | Pioshine | Piostar | Piosys | Piotab | Piotaz | Piotop | Piotrex | Piotrol | Pioz | Piozed | Piozit | Piozone | Piozulin | Pizone | Pizorad | Posinorm | Pozitiv | Precitrol | Pye | Pywohn | Pzone | Pzvio | Sensitab | Wonglita | Zipio</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glustin | Pioglitazone accord | Pioglitazone Actavis | Pioglitazone aurobindo | Pioglitazone Doc | Pioglitazone sandoz | Pioglitazone tecnimede | Pioglitazone Zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Actos</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone | Pioglitazone ffp | Pioglitazone Meiji | Pioglitazone sandoz</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Glitas | Glitter | Glizone | Glustin | Nilgar | Pioday | Pioglit | Piogluc | Pionorm | Piosafe | Piozer</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acgli | Acpio | Acstazone | Acstin | Actazon | Acti-M | Actiem m | Actigly | Actilazone | Actodia | Actogreen | Actopin | Actopis | Actorin | Actos | Actozon | Antos | Atos | Bmi pioglitazone | C tos | Daewoong pioglitazone | Dai act | Dibezone | Dmmet | Dmzone | Emcon | Glezon | Gliact | Glidia | Glitazone | Glitos | Glizone | Gluconon | Glustop | Glutazone | Glyact | Glyta | Greepin | Grutazone | Hypio | Inno.n pioglitazone | K tos | Kaytos | Kukje pioglitazone | New piolita | Newpio | Oglita | Pactos | Pazone | Pictos | Pigli | Piglito | Pigrion | Pigzone | Pioacti | Piodia | Piodin | Piogla | Piogle | Piogli | Pioglin | Pioglisu | Pioglita | Pioglitazone | Pioglon | Pioglu | Piogrin | Piolex | Piolidone | Piolizone | Piomax | Piomed | Piomin | Piona | Piopin | Piora | Pioren | Piorex | Piori | Pioridon | Piorigle | Piorin | Piorita | Pioron | Pios | Piosc | Piot | Piota | Piotazone | Piotic | Piotin | Piotos | Piovex | Piozol | Piozole | Pirizone | Piros | Pitazone | Samsung pioglitazone | Uran | Yulan | Yungjin glitzone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glados | Glustin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Actos | Piodiab | Uniglit</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone accord | Pioglitazone HCL | Pioglitazone Torrent | Zipion</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Actos</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone accord | Pioglitazone Teva | Zipion</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Glitex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Accotaz | Agopar | Deglutzina | Diazatos | Gliozac | Glitacar 1 | Mopro d | Pioglitazona | Pioglitazona antibioticos | Pioglitazona bayer | Pioglitazona biomep | Pioglitazona sanofi-aventis | Pizubet | Plagox | Plitoran | Reazyd | Zactos | Zetric | Zigalta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Piolet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Eden pioglitazone | Nilgar | Piogista | Pionorm | Plutone | Zolital</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon | Pioglitazon sandoz | Pioglitazon Teva Pharma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone accord | Pioglitazone Teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Actos | Noumed pioglitazone | Vexazone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Actos | Diabestat | Piolet | Piolet-30 | Tiazac | Zatium</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actazone | Actos | Glipitone | Glitaz | Glito | Glitter | Insulact | Pio source | Piodart | Piogen | Pioglifar | Pioglitazone | Pioglon | Piolit | Piorance | Piostal | Piotaz | Piouno | Piozar | Piozulin | Ppar | Prialta | Utmos 15l | Zeal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Diglyta | Gliden | Gliter | Glitlite | Glyrol | Oglo | Piobar | Piobetic | Pioglance | Piokure | Piozer | Tagozer | Zolid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone accord | Pioglitazone bioton</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazone | Pioglitazone HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glustin | Pioglitazon ratiopharm | Pioglitazona accord | Pioglitazona Actavis | Pioglitazona Aristo | Pioglitazona Aurobindo | Pioglitazona aurovitas | Pioglitazona bluepharma | Pioglitazona Ciclum | Pioglitazona Cinfa | Pioglitazona farmoz | Pioglitazona generis | Pioglitazona Sandoz | Pioglitazona sarb | Pioglitazona tetrafarma | Pioglitazona Teva Pharma | Pioglitazona Zentiva | Pyadiab</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diabefarm | Glita | Glizona | Pioglit | Pioglitazona 30 mg intas | Pioglitazona prosalud</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glit | Uniglit</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Actos | Glidipion | Lispecip | Pioglitazone accord | Zipion</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Actos | Amalvia | Astrozone | Diab-norm | Diaglitazon | Pioglar | Pioglit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Actos | Apo pioglitazone | Glados | Gleran | Glustin | Ogliton | Pms pioglitazon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Actos | Pioglitazon orion | Pioglitazone | Pioglitazone accord | Pioglitazone Actavis | Pioglitazone teva pharma</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone accord | Pioglitazone Actavis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actos | Gitazone | Gitazone Forte | Glubosil | Militos | Piozone | Senzulin | Utmos</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Actos</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Actos | Dropia | Dyndion | Glifix | Pioforce | Piofox | Piogtan | Piondia | Pixart</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Actos | Befree | Beglipin | Diazone | Glitis | Glufit | Piosugar | Piota | Piozon | Pitazone | Politone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Glutason | Nilgar | Pionorm | Pioz</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Piogen | Piosafe | Zoliglit</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Higlucem | Pacilan | Pioglit | Piomed</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Asglipen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord pioglitazone | Actos | Cipla Pioglitazone</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Glitter | Piomed | Pioz | Piozulin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actos.2020.06">
<a name="Actos.2020.06"></a>Actos (pioglitazone) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Act.2020.02">
<a name="Act.2020.02"></a>Act Pioglitazone (pioglitazone) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Limited; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25941563">
<a name="25941563"></a>Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, et al. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. <i>Ther Adv Endocrinol Metab</i>. 2015;6(2):56-60. doi:10.1177/2042018815574229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/25941563/pubmed" id="25941563" target="_blank">25941563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18718471">
<a name="18718471"></a>Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. <i>Gastroenterology</i>. 2008;135(4):1176-1184. doi:10.1053/j.gastro.2008.06.047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18718471/pubmed" id="18718471" target="_blank">18718471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29222382">
<a name="29222382"></a>American Diabetes Association. 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi:10.2337/dc18-S011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29222382/pubmed" id="29222382" target="_blank">29222382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2022;46(suppl 1):S1-S4. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed June 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi:10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22653981">
<a name="22653981"></a>Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. <i>BMJ</i>. 2012;344:e3645. doi:10.1136/bmj.e3645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/22653981/pubmed" id="22653981" target="_blank">22653981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17135584">
<a name="17135584"></a>Belfort R, Harrison SA, Brown K, et sl. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. <i>N Engl J Med</i>. 2006;355(22):2297-2307. doi:10.1056/NEJMoa060326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17135584/pubmed" id="17135584" target="_blank">17135584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21609444">
<a name="21609444"></a>Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. <i>BMC Clin Pharmacol.</i> 2011;11:5. doi:10.1186/1472-6904-11-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/21609444/pubmed" id="21609444" target="_blank">21609444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31783920">
<a name="31783920"></a>Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. <i>Syst Rev</i>. 2019;8(1):295. doi:10.1186/s13643-019-1200-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/31783920/pubmed" id="31783920" target="_blank">31783920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29223443">
<a name="29223443"></a>Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. <i>Clin Gastroenterol Hepatol</i>. 2018;16(4):558-566.e2. doi:10.1016/j.cgh.2017.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29223443/pubmed" id="29223443" target="_blank">29223443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12680885">
<a name="12680885"></a>Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompôr T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>Br J Clin Pharmacol</i>. 2003;55(4):368-74. doi:10.1046/j.1365-2125.2003.01785.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/12680885/pubmed" id="12680885" target="_blank">12680885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28714183">
<a name="28714183"></a>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2018;67(1):328-357. doi:10.1002/hep.29367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/28714183/pubmed" id="28714183" target="_blank">28714183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27322798">
<a name="27322798"></a>Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. <i>Ann Intern Med</i>. 2016;165(5):305-315. doi:10.7326/M15-1774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/27322798/pubmed" id="27322798" target="_blank">27322798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29037211">
<a name="29037211"></a>de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. <i>Cardiovasc Diabetol</i>. 2017;16(1):134. doi:10.1186/s12933-017-0617-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29037211/pubmed" id="29037211" target="_blank">29037211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16214598">
<a name="16214598"></a>Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet</i>. 2005;366(9493):1279-1289. doi:10.1016/S0140-6736(05)67528-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/16214598/pubmed" id="16214598" target="_blank">16214598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eckland.2000">
<a name="Eckland.2000"></a>Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. <i>Exp Clin Endocrinol Diabetes</i>. 2000;108(suppl 2):S234-S242.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27062661">
<a name="27062661"></a>European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. <i>J Hepatol</i>. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/27062661/pubmed" id="27062661" target="_blank">27062661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22153789">
<a name="22153789"></a>Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. <i>Fertil Steril. </i>2012;97(1):28-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/22153789/pubmed" id="22153789" target="_blank">22153789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19623674">
<a name="19623674"></a>Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure associated with rosiglitazone and pioglitazone. <i>Pharmacoepidemiol Drug Saf</i>. 2009;18(12):1238-1243. doi:10.1002/pds.1804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/19623674/pubmed" id="19623674" target="_blank">19623674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12871871">
<a name="12871871"></a>Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and Metformin in Obese Women With Polycystic Ovary Syndrome Not Optimally Responsive to Metformin. <i>Hum Reprod. </i>2003;18(8):1618-1625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/12871871/pubmed" id="12871871" target="_blank">12871871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25727309">
<a name="25727309"></a>Hu D, Wu CQ, Li ZJ, et al. Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: an in vitro model in mitochondria. <i>Toxicol Appl Pharmacol</i>. 2015;284(2):134-141. doi:10.1016/j.taap.2015.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/25727309/pubmed" id="25727309" target="_blank">25727309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inzucchi.1">
<a name="Inzucchi.1"></a>Inzucchi SE. Thiazolidinediones in the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27127397">
<a name="27127397"></a>Jearath V, Vashisht R, Rustagi V, Raina S, Sharma R. Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction. <i>J Pharmacol Pharmacother</i>. 2016;7(1):41-43. doi:10.4103/0976-500X.179363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/27127397/pubmed" id="27127397" target="_blank">27127397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886418">
<a name="26886418"></a>Kernan WN, Viscoli CM, Furie KL, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. <i>N Engl J Med</i>. 2016;374(14):1321-1331. doi:10.1056/NEJMoa1506930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/26886418/pubmed" id="26886418" target="_blank">26886418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(suppl 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. <i>J Am Geriatr Soc</i>. 2012;60(12):2342-2356. doi:10.1111/jgs.12035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15266041">
<a name="15266041"></a>Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. <i>Ann Pharmacother</i>. 2004;38(9):1419-1423. doi:10.1345/aph.1E072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/15266041/pubmed" id="15266041" target="_blank">15266041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11900497">
<a name="11900497"></a>May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. <i>Ann Intern Med</i>. 2002;136(6):449-452. doi:10.7326/0003-4819-136-6-200203190-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/11900497/pubmed" id="11900497" target="_blank">11900497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583425">
<a name="14583425"></a>Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. <i>Endocr Pract</i>. 2003;9(5):406-416. doi:10.4158/EP.9.5.406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/14583425/pubmed" id="14583425" target="_blank">14583425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693998">
<a name="14693998"></a>Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i>. 2004;27(1):256-263. doi:10.2337/diacare.27.1.256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/14693998/pubmed" id="14693998" target="_blank">14693998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15642799">
<a name="15642799"></a>Ortega-Gonzalez C, Cardoza L, Coutino B, et al. Insulin Sensitizing Drugs Increase the Endogenous Dopaminergic Tone in Obese Insulin-Resistant Women With Polycystic Ovary Syndrome. <i>J Endocrinol.</i> 2005;184(1):233-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/15642799/pubmed" id="15642799" target="_blank">15642799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18423625">
<a name="18423625"></a>Ota H, Goto T, Yoshioka T, et al. Successful Pregnancies Treated With Pioglitazone in Infertile Patients With Polycystic Ovary Syndrome. <i>Fertil Steril.</i> 2008;90(3):709-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18423625/pubmed" id="18423625" target="_blank">18423625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29683100">
<a name="29683100"></a>Pavlova V, Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone therapy and fractures: Systematic review and meta-analysis. <i>Endocr Metab Immune Disord Drug Targets</i>. 2018;18(5):502-507. doi:10.2174/1871530318666180423121833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29683100/pubmed" id="29683100" target="_blank">29683100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19007650">
<a name="19007650"></a>Practice Committee of American Society for Reproductive Medicine. Use of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome. <i>Fertil Steril.</i> 2008;90(5)(suppl):S69-S73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/19007650/pubmed" id="19007650" target="_blank">19007650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23930133">
<a name="23930133"></a>Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. <i>Hepat Mon</i>. 2013;13(5):e9270. doi:10.5812/hepatmon.9270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/23930133/pubmed" id="23930133" target="_blank">23930133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20427778">
<a name="20427778"></a>Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <i>N Engl J Med</i>. 2010;362(18):1675-1685. doi:10.1056/NEJMoa0907929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/20427778/pubmed" id="20427778" target="_blank">20427778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24669954">
<a name="24669954"></a>Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. <i>Expert Opin Drug Metab Toxicol</i>. 2014;10(6):839-857. doi:10.1517/17425255.2014.902444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/24669954/pubmed" id="24669954" target="_blank">24669954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11431595">
<a name="11431595"></a>Scheen AJ. Thiazolidinediones and liver toxicity. <i>Diabetes Metab</i>. 2001;27(3):305-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/11431595/pubmed" id="11431595" target="_blank">11431595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30734043">
<a name="30734043"></a>Spence JD, Viscoli CM, Inzucchi SE, et al; IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. <i>JAMA Neurol</i>. 2019;76(5):526-535. doi:10.1001/jamaneurol.2019.0079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/30734043/pubmed" id="30734043" target="_blank">30734043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12706937">
<a name="12706937"></a>Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. <i>J Am Coll Cardiol</i>. 2003;41(8):1394-1398. doi:10.1016/s0735-1097(03)00159-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/12706937/pubmed" id="12706937" target="_blank">12706937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476615">
<a name="29476615"></a>Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. <i>Cancer Med</i>. 2018;7(4):1070-1080. doi:10.1002/cam4.1354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29476615/pubmed" id="29476615" target="_blank">29476615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19670918">
<a name="19670918"></a>Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. <i>Drug Saf</i>. 2009;32(9):787-800. doi:10.2165/11316510-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/19670918/pubmed" id="19670918" target="_blank">19670918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27935736">
<a name="27935736"></a>Viscoli CM, Inzucchi SE, Young LH, et al; IRIS Trial Investigators. Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial. <i>J Clin Endocrinol Metab</i>. 2017;102(3):914-922. doi:10.1210/jc.2016-3237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/27935736/pubmed" id="27935736" target="_blank">27935736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35252271">
<a name="35252271"></a>Yen FS, Hsu CC, Wei JC, Hou MC, Hwu CM. Selection and warning of evidence-based antidiabetic medications for patients with chronic liver disease. <i>Front Med (Lausanne)</i>. 2022;9:839456. doi:10.3389/fmed.2022.839456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/35252271/pubmed" id="35252271" target="_blank">35252271</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10216 Version 460.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
